Company Analysis
Sign in

Entrada Therapeutics, Inc. (TRDA)

Nasdaq: TRDA · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2016
Full chart Alerts Compare
Grade5.2
◀ Past 5.9● Present 4.9▶ Future 5.0
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

6 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Entrada Therapeutics, Inc.’s names, not what it holds today.

Patents granted
6
6 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and none in 2023
Applications published
24
9 of them in 2025
Names they are printed under
3
its own name, a former name
By yearGrantedApplications published
'17'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals3
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
Entrada Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
22 published
Entrada Therapeutics, Inc. its own name
US, as the owner printed on each patent
6 granted
0 published
CYCLOPORTERS, INC. a former name
named as the applicant on its applications, in US
0 granted
2 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Aug 5, 202512,378,267Synthesis of FMOC-protected morpholino monomers and oligomersOrganic fine chemistryEntrada Therapeutics, Inc.
May 21, 202411,987,821Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathyPharmaceuticalsEntrada Therapeutics, Inc.
Jan 18, 202211,225,506Cell penetrating peptides and methods of making and using thereofPharmaceuticalsEntrada Therapeutics, Inc.
Nov 9, 202111,168,310Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathyPharmaceuticalsEntrada Therapeutics, Inc.
Oct 27, 202010,815,276Cell penetrating peptides and methods of making and using thereofPharmaceuticalsEntrada Therapeutics, Inc.
Apr 21, 202010,626,147Cell penetrating peptides and methods of making and using thereofPharmaceuticalsEntrada Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Sep 18, 20252025/0289851CYCLIC PEPTIDES FOR DELIVERING THERAPEUTICSBiotechnologyEntrada Therapeutics, Inc.
Jul 31, 20252025/0243244CYCLIC CELL PENETRATING PEPTIDESBiotechnologyEntrada Therapeutics, Inc.
Jul 17, 20252025/0228953INTRACELLULAR TARGETING OF OLIGONUCLEOTIDESPharmaceuticalsEntrada Therapeutics, Inc.
Apr 24, 20252025/0129365COMPOUNDS AND METHODS FOR SKIPPING EXON 44 IN DUCHENNE MUSCULAR DYSTROPHYPharmaceuticalsEntrada Therapeutics, Inc.
Apr 10, 20252025/0115885COMPOSITIONS AND METHODS FOR TREATING MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOPATHYPharmaceuticalsEntrada Therapeutics, Inc.
Feb 13, 20252025/0051780COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICINGBiotechnologyEntrada Therapeutics, Inc.
Feb 13, 20252025/0051393COMPOSITIONS AND METHODS FOR MODULATING INTERFERON REGULATORY FACTOR-5 (IRF-5) ACTIVITYPharmaceuticalsEntrada Therapeutics, Inc.
Jan 9, 20252025/0011774ANTISENSE COMPOUNDS AND METHODS FOR TARGETING CUG REPEATSBiotechnologyEntrada Therapeutics, Inc.
Jan 9, 20252025/0011367CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOFPharmaceuticalsEntrada Therapeutics, Inc.
Dec 19, 20242024/0417429COMPOSITIONS AND METHODS FOR SKIPPING EXON 45 IN DUCHENNE MUSCULAR DYSTROPHYPharmaceuticalsEntrada Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 8 · Biotechnology 6.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton TRDA · research, not advice